- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.11.24 | New England Biolabs opens new manufacturing facility in UK | ||
| 07.11.24 | Plus Therapeutics partners with SpectronRx for CNS therapy development | ||
| 06.11.24 | Insignis Therapeutics' IN-001 clinical programme receives positive FDA response | ||
| 05.11.24 | Ring Therapeutics signs partnerships to advance R&D in biomedical sciences | ||
| 04.11.24 | NEOGAP and NorthX Biologics partner for cancer cell therapy production | ||
| 01.11.24 | Electra Therapeutics secures FDA ODD status for HLH treatment | ||
| 31.10.24 | Shanghai Henlius Biotech, Organon announce FDA acceptance of BLA for HLX14 | ||
| 30.10.24 | FDA expands approval for Shorla's JYLAMVO to paediatric patients | ||
| 29.10.24 | Kivu Bioscience secures $92m in Series A funding for ADC development | ||
| 28.10.24 | FDA grants IND clearance for RiboX's RXRG001 | ||
| 25.10.24 | Lyell signs agreement to acquire ImmPACT Bio | ||
| 24.10.24 | FDA issues CRL to PharmaTher's ketamine ANDA | ||
| 23.10.24 | TerSera acquires global rights to MacroGenics' MARGENZA for breast cancer treatment | ||
| 22.10.24 | Samsung Biologics signs $1.24bn manufacturing deal with Asian pharma company | ||
| 21.10.24 | Novartis gets positive CHMP opinion for Kisqali in early breast cancer | ||
| 18.10.24 | AscellaHealth acquires specialty pharmaceutical wholesaler CHAPPER healthcare | ||
| 17.10.24 | Astria Therapeutics' navenibart gains orphan medicinal status from EC | ||
| 16.10.24 | RTI partners with Codetta Bio to boost healthcare innovation | ||
| 15.10.24 | Samsung Biologics launches biopharmaceutical platform S-HiCon | ||
| 14.10.24 | Stealth's elamipretide gains FDA advisory committee support for Barth syndrome | ||
| 11.10.24 | Volixibat gains FDA breakthrough therapy designation | ||
| 10.10.24 | insitro collaborates with Lilly on metabolic disease treatments | ||
| 09.10.24 | PsychoGenics secures NIH contract to identify new pain therapeutics | ||
| 08.10.24 | Neuvivo files NDA seeking FDA approval for ALS treatment | ||
| 07.10.24 | AstraZeneca to license CSPC Pharmaceutical's lipid-lowering therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
